4LN2 Stock Chart & Stats
€17.22
€1.20(7.46%)
At close: 4:00 PM EDT
€17.22
€1.20(7.46%)
Day’s Range― - ―
52-Week Range€2.58 - €30.77
Previous CloseN/A
Volume0.00
Average Volume (3M)1.87K
Market Cap
€426.70M
Enterprise Value€1.25K
Total Cash (Recent Filing)€237.93M
Total Debt (Recent Filing)€91.05M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Nov 17, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.45
Shares Outstanding58,138,990
10 Day Avg. Volume535
30 Day Avg. Volume1,869
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.39
Price to Sales (P/S)0.00
P/FCF Ratio-18.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€23.70Price Target Upside37.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.34
Revenue Forecast (FY)€79.14M
Bulls Say, Bears Say
Bulls Say
Primary Clinical EfficacyThe statistically significant HOPE-3 primary endpoint provides the core clinical evidence for deramiocel’s potential value in DMD. Demonstrated preservation of upper-limb function could support a focused approval and create a durable therapeutic position if regulatory review is favorable.
Peer-Reviewed ValidationPublication of the pivotal dataset in The Lancet adds independent scientific visibility and credibility to Capricor’s lead program. Peer-reviewed evidence can strengthen discussions with regulators, clinicians, and partners while supporting confidence in the durability of the clinical record.
Cash And Manufacturing ReadinessA substantial cash position and operational in-house GMP capability give Capricor resources to advance regulatory work and prepare for a potential launch. Internal manufacturing may also improve control over supply preparation, though continued spending means this flexibility must be managed carefully.
Bears Say
FDA Review DelayThe three-month FDA review extension postpones a potential approval decision and delays any transition toward commercial revenue. The major-amendment classification also signals additional regulatory review requirements, extending execution timelines and preserving uncertainty around the eventual indication.
Persistent Losses And No RevenueCapricor remains pre-commercial, with no reported quarterly revenue and losses widening as operating expenses rise. Until a product is approved and launched, the company lacks recurring customer revenue to offset development and preparation costs, keeping earnings performance highly dependent on external funding.
Ongoing Cash BurnNegative operating and free cash flow across each reported period shows that Capricor’s current operations do not self-fund development. Continued cash burn can reduce financial flexibility over time and increase reliance on financing or other funding sources before commercial revenues begin.
Capricor Therapeutics News
4LN2 FAQ
What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was €2.58 and its highest was €30.77 in the past 12 months.
What is Capricor Therapeutics’s market cap?
Capricor Therapeutics’s market cap is €426.70M.
When is Capricor Therapeutics’s upcoming earnings report date?
Capricor Therapeutics’s upcoming earnings report date is Nov 17, 2026 which is in 51 days.
How were Capricor Therapeutics’s earnings last quarter?
Capricor Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.6 earnings per share for the quarter, missing the consensus estimate of -€0.505 by -€0.095.
Is Capricor Therapeutics overvalued?
According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
Does Capricor Therapeutics pay dividends?
Capricor Therapeutics does not currently pay dividends.
What is Capricor Therapeutics’s EPS estimate?
Capricor Therapeutics’s EPS estimate is -0.12.
How many shares outstanding does Capricor Therapeutics have?
Capricor Therapeutics has 58,138,990 shares outstanding.
What happened to Capricor Therapeutics’s price movement after its last earnings report?
Capricor Therapeutics reported an EPS of -€0.6 in its last earnings report, missing expectations of -€0.505. Following the earnings report the stock price went up 90.785%.
Which hedge fund is a major shareholder of Capricor Therapeutics?
Currently, no hedge funds are holding shares in DE:4LN2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Capricor Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€23.70 (37.65% Upside)
€23.70 (37.65% Upside)
Blogger Sentiment
Bullish
DE:4LN2 Sentiment 82%
Sector Average 63%
Sector Average 63%
Technicals
SMA
Negative
20 days / 200 days
Momentum
28.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
176.06%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
4LN2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced meaningful clinical and regulatory progress (Lancet publication, statistically significant primary HOPE‑3 endpoint for upper limb function, established safety exposure, operational in‑house manufacturing and $237.9M cash) against substantial near‑term challenges (AdCom vote against the cardiomyopathy question, mixed secondary endpoint results, no revenue, rising operating expenses and widening losses, a Form 483 observation, paused non‑Daramycin pipeline work, and an ongoing commercial dispute with NS Pharma). Management has a clear path to submit an amendment focused on the primary skeletal muscle indication and the FDA indicated willingness to review it, but regulatory and financial risks remain in the near term.View all DE:4LN2 earnings summaries4LN2 Stock 12 Month Forecast
Average Price Target
€23.70
▲(37.65% Upside)